In the RECAM randomized phase III trial, chiglitazar (32 mg and 48 mg) as add‑on to metformin produced clinically meaningful HbA1c reductions and favorable lipid changes versus placebo over 24 weeks, with a tolerable safety profile characterized mainly by modest weight gain and mild oedema.